###### Strengths and limitations of this study

-   This is the first systematic review of randomised controlled trials to assess the benefits and risks associated with active treatment targeted at underlying disease versus palliative in the end-of-life setting.

-   One of the strengths of this study was the extensive, systematic literature search performed to identify all available randomised controlled trials in terminally ill patients.

-   A limitation of this systematic review is the availability of small number of studies with overall survival data.

Introduction {#s1}
============

The diagnosis of a terminal illness for patients is shattering news.[@R1] Following the diagnosis, patients along with their families are faced with several complex decisions relating to medical, spiritual, legal, or existential issues.[@R1] The most concerning decision for patients and families alike following diagnosis of terminal illness relates to the choice of medical strategy of either opting for active treatment targeted at underlying disease (TTD) which can potentially be life-prolonging or curative, versus palliative care (PC) where the primary focus is on providing symptomatic relief and improving quality of life (QOL).[@R2] The US Medicare regulations recommend PC for patients with terminal illness, ideally in hospice setting, if the expected survival is \<6 months; conversely, PC or referral to hospice is considered inappropriate if expected survival is \<6 months. However, findings from several studies show that application of these recommendations is far from optimal in real-life setting. For example, around 40% of patients with advanced lung cancer continued aggressive therapy through the final month of life.[@R3] Overall, over 60% of patients with cancer receive aggressive TTD within the past 3 months of life.[@R4] In fact, during the last decade, the number of patients receiving aggressive therapy within the last month of life grew[@R8] which also reflects the increased healthcare spending in the past 6 months of life. On the other hand, use of hospice in the past 3 days of life minimally increased from 14.3% to 17%.[@R2] [@R9] [@R10] In short, patients with terminal illness are not receiving care as per the professional societies\' or Medicare recommendations.[@R2]

There are several reasons for not delivering the appropriate care to patients with terminal illness. One of the main reasons is lack of evidence or conflicting evidence related to benefits and harms associated with TTD versus PC.[@R2] Findings from a randomised controlled trial (RCT) assessing the role of supportive care versus supportive care in addition to TTD in patients with transitional cell carcinoma of urothelial tract demonstrated no survival advantage with a combination treatment approach.[@R11] Another study by Schmid *et al*[@R12] which assessed the role of radiotherapy or chemotherapy (ie, TTD) compared with no treatment in patients with inoperable squamous carcinoma of the oesophagus showed no survival advantage with TTD. However, results from a RCT comparing supportive care versus supportive care plus TTD in patients with metastatic non-small cell lung cancer showed a survival advantage with TTD.[@R13]

Given that physicians are not accurate in establishing patients\' prognosis for course of disease or death,[@R14] [@R15] to make informed choice, patients and physicians alike need reliable evidence on benefits and risks associated with TTD versus PC. Accordingly, we performed a systematic review with a goal to synthesise all available evidence to reliably assess the efficacy and safety of TTD compared with PC in patients with terminal illness (with expected survival of \<6 months).

Methods {#s2}
=======

This systematic review was performed according to a prespecified protocol and is reported according to PRISMA guidelines.[@R16]

Eligibility criteria {#s2a}
--------------------

Any RCT enrolling patients with clearly stated predicted median survival of \<6 months comparing an established TTD versus PC alone was eligible for inclusion. Studies of novel TTD treatments within a context of clinical trials were excluded. We also excluded trials comparing add-on PC to two active treatments. The distinction between PC versus TTD was made based on the original investigators intent (ie, symptom management vs curative or life prolonging intent) as stated in the introduction or methods of included studies.

Search and study selection {#s2b}
--------------------------

A comprehensive search of Medline and Cochrane electronic databases, with no language restriction, was undertaken from inception to 19 October 2016. Search strategy is provided in online [supplementary appendix 1](#SM1){ref-type="supplementary-material"}. Two authors (AK and TR) reviewed all retrieved titles/abstracts and full-text articles independently. A third author (BD) reviewed any disagreements to arrive at consensus.
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Data collection {#s2c}
---------------

Data were abstracted on study and patient characteristics, treatment, and outcomes (overall survival (OS), QOL, treatment-related mortality (TRM), and adverse events). Data extraction was performed independently by two authors (TR and FAK) using a standardised data extraction form. The corresponding author (BD) resolved any disagreement during the data extraction process. Risk of bias was assessed using Cochrane Risk of Bias Tool.[@R17] The overall assessment of methodological quality was performed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.[@R18]

Statistical analysis {#s2d}
--------------------

When appropriate, data were pooled for each outcome. Dichotomous data were summarised using risk ratio (RR) based on the number of events and total number of participants and pooled under random-effects model. In regards to time-to-event data, HR and 95% CIs were extracted, whenever reported. Otherwise, total number of participants and events per arm and the p value were obtained in order to calculate the observed minus expected value (O-E) and variance as per method by Tierney *et al*.[@R19] Time-to-event data were pooled using generic inverse variance under the random-effects model. All data are reported with 95% CI. Calculation of the I^2^ statistic was used to assess for heterogeneity. An I^2^ \<30% was considered low heterogeneity, between 30% and 50% moderate heterogeneity and over 50% high heterogeneity.[@R20] The analyses were performed using Review Manager software (Review Manager (RevMan) \[program\]. Version 5.3 version. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results {#s3}
=======

Study selection {#s3a}
---------------

The initial search identified 8252 articles of which 10 RCTs (15 comparisons, 1549 patients) met the inclusion criteria.[@R11] [@R21] The study selection process is illustrated in [figure 1](#BMJOPEN2016014661F1){ref-type="fig"}.

![Flow diagram depicting the identification and selection of eligible studies for inclusion in the systematic review and meta-analysis.](bmjopen2016014661f01){#BMJOPEN2016014661F1}

Characteristics of included studies {#s3b}
-----------------------------------

As illustrated in [table 1](#BMJOPEN2016014661TB1){ref-type="table"}, all included studies enrolled patients with cancer. The majority of studies compared disease-targeted chemotherapy (12/15 comparisons) to PC alone[@R11] [@R21] while the remaining three studies used targeted drug therapy,[@R27] radiotherapy,[@R12] and hormone therapy[@R26] on the TTD arm. The PC arm mainly consisted of analgesics (8/15 comparisons),[@R11] [@R13] [@R22] [@R25] [@R26] blood product transfusions (7/15 comparisons),[@R11] [@R13] [@R23] [@R25] and palliative radiotherapy (5/15 comparisons).[@R13] [@R22] [@R23]

###### 

Study and patient characteristics

  Study, year         Years        Patients enrolled   Cancer type    Age (TTD vs PC)                                TTD            PC offered in addition to TTD   PC                                                                                        Expected median survival \<6 months
  ------------------- ------------ ------------------- -------------- ---------------------------------------------- -------------- ------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------
  Bellmunt, 2009      2003--2006   337                 Urothelial     NR                                             Chemotherapy   Yes                             Pain medication, palliative chemotherapy, supportive care, antibiotics, corticosteroids   Yes
  Cartei, 1993        NR           102                 Lung           Median (range): 57 (39--71) vs 56 (41--73)     Chemotherapy   Yes                             Pain medication, radiotherapy, supportive care                                            Yes
  Ciuleanu, 2009      2004--2006   303                 Pancreatic     Median (range): 58 (27--78) vs 57 (29--80)     Chemotherapy   Yes                             Pain medication, supportive care, appetite stimulators                                    Yes
  De Marinis, 1999a   1990--1993   61                  Lung           NR                                             Chemotherapy   Unclear                         Pain medication, radiotherapy, steroids, progestins                                       Yes
  De Marinis, 1999b   1990--1993   63                  Lung           NR                                             Chemotherapy   Unclear                         Pain medication, radiotherapy, steroids, progestins                                       Yes
  De Marinis, 1999c   1990--1993   64                  Lung           NR                                             Chemotherapy   Unclear                         Pain medication, radiotherapy, steroids, progestins                                       Yes
  Lissoni, 1994a      NR           50                  Pancreatic     Median (range): 56 (39--71) vs 57 (50--74)     Chemotherapy   Yes                             Pain medication, supportive care, steroids, antiemetics, ansioliticos                     Yes
  Lissoni, 1994b      NR           50                  Solid tumors   Median (range): 56 (38--72) vs 58 (42--71)     Drug therapy   Yes                             Supportive care                                                                           Yes
  Ranson, 2000        1995--1997   157                 Lung           Median (range): 65 (37--78) vs 64 (23--82)     Chemotherapy   Yes                             Radiotherapy, supportive care, corticosteroids, antibiotics, antiemetics                  Yes
  Schmid, 1993a       1987--1989   87                  Esophageal     Median: 55 vs 53                               Radiotherapy   Unclear                         Intubation only                                                                           Yes
  Schmid, 1993b       1987--1989   86                  Esophageal     Median: 55 vs 53                               Chemotherapy   Unclear                         Intubation only                                                                           Yes
  Selawry, 1977a      NR           150                 Lung           Median: 62 vs 59                               Chemotherapy   Unclear                         NR                                                                                        Yes
  Selawry, 1977b      NR           152                 Lung           Median: 59 vs 59                               Chemotherapy   Unclear                         NR                                                                                        Yes
  Xinopoulos, 2008    NR           73                  Pancreatic     Mean (range): 66.5 (59--73) vs 66.6 (58--73)   Chemotherapy   Unclear                         Plastic biliary endoprosthesis placement as needed                                        Yes

NR, not reported; PC, palliative care; TTD, treatment targeted at underlying disease.

Risk of bias in included studies {#s3c}
--------------------------------

The overall methodological quality of included studies ranged from moderate to low. As shown in [figure 2](#BMJOPEN2016014661F2){ref-type="fig"}, 80% of included studies (8/10) reported method of randomisation sequence generation. However, only 20% (2/10) of included studies were judged to have adequate allocation concealment and only 10% (1/10) involved blinding of participants/personnel or outcome assessors. Ninety per cent of studies (9/10) performed analysis as per intention-to-treat principle and 70% (7/10) studies reported all outcomes and did not involve selective reporting of outcomes.

![Risk of bias in included studies.](bmjopen2016014661f02){#BMJOPEN2016014661F2}

Outcomes {#s3d}
--------

Patient outcomes are summarised in [table 2](#BMJOPEN2016014661TB2){ref-type="table"}. [Figure 3](#BMJOPEN2016014661F3){ref-type="fig"} shows a forest plot comparing effects of TTD versus PC on the OS. OS was reported by seven RCTs (eight comparisons, 1158 patients).[@R11] [@R23] [@R27] The pooled results showed no statistically significant difference in OS between TTD and PC (HR (95% CI) 0.85 (0.71 to 1.02)). The heterogeneity between pooled studies was high (I^2^=62.1%). Four studies included QOL as an outcome; however, data were not extractable for pooling.[@R11] [@R23] [@R24] [@R27] Only two RCTs (668 patients) reported TRM.[@R11] [@R25] There was no statistically significant difference in TRM between TTD and PC (RR (95% CI) 0.92 (0.31 to 2.76)). There was no heterogeneity between pooled studies (I^2^=0%). Seven RCTs (10 comparisons)[@R11] [@R13] [@R22] discussed adverse events but only three (three comparisons)[@R11] [@R23] [@R25] reported comparative data for both study arms. Overall, grade three or four adverse events were significantly more common on the TTD arm compared with PC (see [table 2](#BMJOPEN2016014661TB2){ref-type="table"}).

###### 

Evidence table for TTD versus PC alone in terminally ill adults GRADE evidence profile

  ----------------------------------
  ![](bmjopen2016014661ileq01.jpg)
  ----------------------------------

**GRADE Working Group grades of evidence High quality**: We are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate quality**: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low quality**: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

**Very low quality**: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1\. High heterogeneity between studies.

2\. Majority of studies not reporting data on outcome.

3\. Wide CIs.

Any text which is either bold or in grey shading represents the risk associated with TTD.

\**The risk in the intervention group* (and its 95% CI) is based on the assumed risk in the comparison group and the *relative effect* of the intervention (and its 95% CI).

†\<1: Poorer results with PC; \>1: poorer results with TTD; 1=no difference between effects of PC and TTD.

GRADE, Grading of Recommendations Assessment, Development and Evaluation; OS, overall survival; PC, palliative care; QOL, quality of life; RCTs, randomised controlled trials; RR, risk ratio; TRM, treatment-related mortality; TTD, treatment targeted at underlying disease.

![Forest plot for overall survival. The summary estimate (HR) from individual studies is indicated by rectangles with lines representing the 95% CIs. The summary pooled estimate from all studies is represented by the diamond and the stretch of the diamond indicates the corresponding 95% CI. Summary estimates that fall to the left of the line (HR\<1) indicate favourable survival on the treatment targeted at underlying disease (TTD) arm. Summary estimates that fall to the right of the line (HR\>1) indicate favourable survival on the palliative care (PC) arm.](bmjopen2016014661f03){#BMJOPEN2016014661F3}

Discussion {#s4}
==========

The findings of this systematic review have several important implications for physicians, patients and policymakers. Physicians are obligated legally and ethically to provide patients with evidence on alternative management options in the end-of-life setting. Some states such as New York and California make the failure to discuss the management alternatives in terminal setting punishable by law (up to \$5000 for repeated offences, and wilful violations by a jail term of up to 1 year).[@R28] However, repeated assessments of the quality of decision-making in the end-of-life setting over the last two decades continue to show that is inadequate.[@R1] In 2014, 55 million people died worldwide, the vast majority of whom did not receive adequate end-of-life care.[@R29] The fundamental reason for this state of affairs is the lack of reliable estimates about the efficacy and safety of active treatment (TTD) versus PC in patients in terminal phase of their lives. Even though it is known that PC does improve survival when it is added to TTD,[@R30] it is not known if TTD is superior to PC alone. Our systematic review fills this void. To the best of our knowledge, this is the first systematic review assessing the role of TTD compared with PC in patients with terminal illness with expected survival of \<6 months. The findings showed that overall TTD compared with PC does not improve survival and is associated with significantly higher incidence of fatigue, nausea/vomiting, mucositis, grade III/IV neuropathy, anaemia, leukopenia, neutropaenia, and myalgia leading to poor QOL.

Decisions to discontinue with TTD and focus on PC are accompanied by an assessment that such treatments would be ineffective, potentially harmful or medically futile.[@R2] Therefore, for patients and physicians our systematic review provides a long-awaited empirical answer on benefits and harms associated with TTD compared with PC. Based on research synthesis of all available randomised evidence, we found that patients with terminal illness and their physicians can avoid the impulse to 'try anything or everything' in desire to potentially prolong survival due to uncertainty if TTD is superior to PC. We demonstrated that this is not the case, and, in fact, TTD is typically more toxic. Our results, therefore, can be used to facilitate shared decision-making in end of life care setting, which is often difficult for physicians, patients and families. Our results may assist patients and physicians when making a decision on whether to continue or discontinue TTD and make an informed choice between TTD versus PC. Given that unrealistic patient and physician expectations are key barriers to improving the quality of end-of-life care,[@R31] providing reliable evidence to 'serve as a neutral arbiter',[@R32] our results may help assure patients, physicians and family members that focus on PC and hospice referral may not compromise the patient life expectancy but, in fact, result in higher quality of end-of-life care. If acted on, our findings may help improve referral to hospice; as stated above, over 16% of patients with cancer who die in hospice care are in hospice for \<3 days while many do not receive hospice care at all.[@R33] [@R34] Similarly, our results may minimise unnecessary suffering as many patients with a terminal prognosis receive chemotherapy in the last month of life.[@R35] Therefore, the findings from our systematic review may inform the referral to hospice for patients with terminal illness and avoid the late referrals to hospice; early referrals to hospice can help patients enjoy the full benefits of hospice care, more fulfilling remaining days of their lives while avoiding toxicity of unnecessary treatment. For policymakers, the evidence from this systematic review should promote a discussion on reimbursement practices where providers are more likely to be reimbursed for shared conversations with patients instead of administering aggressive therapy.[@R36]

Our study has several limitations, mainly due to selective outcome reporting and methodological quality of the primary studies eligible for this analysis. For example, of the 10 RCTs that met the inclusion criteria only 7 (eight comparisons) reported survival as an outcome, which is surprising, given that life expectancy is the most important outcome for patients with terminal illness.[@R37] Additionally, QOL was also measured and reported in only 4 of the 10 studies; these studies used different QOL measures making comparisons more difficult. However, despite selective reporting in individual studies, these findings represent the totality of the currently available evidence. The overall methodological quality of included studies ranged from moderate to low, which can be attributed to lack of allocation concealment and blinding. Whether, the lack of allocation concealment is an artefact of reporting or conduct[@R38] could not be determined since study protocols were not available. Regarding the lack of blinding, we believe this issue is not a major concern because survival was the main outcome for our study; mortality is an objective outcome and blinding is important in cases where the outcome is subjective.

In summary, our systematic review of available RCTs in patients with terminal illness shows that TTD compared with PC does not impact survival and is associated with increased toxicity. The results provide assurance to physicians, patients, and family that the patients with estimated survival of \<6 months would be better off by referral to hospice. Whether new drugs with potentially life prolonging potential and safer toxicity profile will challenge these findings can only be determined in future well designed RCTs with adequate power. The average sample size in included studies was 124, which provides 15% power to detect a 15% survival difference (HR of 0.85 observed in this meta-analysis). To detect a 15% survival difference with 80% power and a 0.05 level of significance, a sample size of 1194 patients is needed. In the mean time, the physicians should be judicious in actively treating patients whose estimated survival is \<6 months and provide information on benefits and risks associated with TTD versus PC to facilitate shared decision-making.
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